A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

Wonsuk Shin,1 Kyoung Soo Lim,1 Min-Kyoung Kim,1 Hyun Sook Kim,2 Jihwa Hong,3 Stanford Jhee,3 Joseph Kim,3 Sungeun Yoo,4 Yeon-Tae Chung,4 Jae Moon Lee,4 Doo-Yeoun Cho1 1Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Repu...

Full description

Bibliographic Details
Main Authors: Shin W, Lim KS, Kim MK, Kim HS, Hong J, Jhee S, Kim J, Yoo S, Chung YT, Lee JM, Cho DY
Format: Article
Language:English
Published: Dove Medical Press 2019-03-01
Series:Drug Design, Development and Therapy
Subjects:
first-in-human
KM-819
pharmacokinetics
pharmacodynamics
safety
Online Access:https://www.dovepress.com/a-first-in-human-study-to-investigate-the-safety-tolerability-pharmaco-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/a-first-in-human-study-to-investigate-the-safety-tolerability-pharmaco-peer-reviewed-article-DDDT

Similar Items